New insider activity at Jazz Pharmaceuticals ( (JAZZ) ) has taken place on November 20, 2025.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
In recent transactions involving Jazz Pharmaceuticals stock, Director Rick Winningham sold 5,500 shares, amounting to a total of $994,675. Additionally, SVP & CAO Patricia Carr sold 5,319 shares, with the sale valued at $968,402.
Recent Updates on JAZZ stock
Jazz Pharmaceuticals has seen a series of price target increases from multiple firms following positive developments in its HERIZON-GEA-01 trial data. Truist raised its price target due to the potential of Ziihera, which could exceed $2 billion in peak sales, viewing it as a ‘pipeline-in-a-drug’ with significant upside in HER2+ cancers. Baird also increased its target, citing the trial’s results as a best-case scenario. BofA highlighted the favorable Phase 3 data for Ziihera in gastric cancer, estimating a substantial market opportunity. Wells Fargo pointed to zanidatamab’s potential as a new standard of care in gastroesophageal adenocarcinoma, with a significant peak opportunity in both GEA and breast cancer. Jefferies noted the trial’s efficacy against adenocarcinoma, expecting Zani to become the standard of care in first-line GEA. These developments have led to a notable 20.6% rise in Jazz Pharmaceuticals’ stock price.
Spark’s Take on JAZZ Stock
According to Spark, TipRanks’ AI Analyst, JAZZ is a Neutral.
Jazz Pharmaceuticals’ overall stock score is driven by strong earnings call performance and positive technical indicators, despite challenges in financial performance and valuation. The company’s strategic advancements and record revenues are significant positives, but profitability issues and potential future competition pose risks.
To see Spark’s full report on JAZZ stock, click here.
More about Jazz Pharmaceuticals
YTD Price Performance: 42.28%
Average Trading Volume: 905,461
Technical Sentiment Signal: Buy
Current Market Cap: $10.7B